SARAH MICHELLE LIVE REVIEW TEST BANK 2026/2027 |
Newest Actual Exam Q&A | Verified Detailed Answers |
Graded A+ | Pass Guaranteed - A+ Graded
SECTION 1: CARDIOVASCULAR SYSTEM - NEWEST CONCEPTS
(30 Questions)
Q1: A 58-year-old patient with type 2 diabetes, eGFR 45 mL/min/1.73 m², and UACR 350
mg/g presents for diabetes management. According to the 2026 ADA Standards of
Care, which medication class should be prioritized as a co-primary therapeutic goal
alongside glucose lowering?
A. Sulfonylureas, as they provide rapid glucose reduction and are safe in CKD stage 3b
B. DPP-4 inhibitors, because they have proven cardiovascular benefit in all patients with
diabetes
C. SGLT2 inhibitors, due to their established cardiorenal protective benefits regardless
of baseline A1C or eGFR down to 20 mL/min/1.73 m² [CORRECT]
D. Thiazolidinediones, as they reduce insulin resistance and improve lipid profiles in
diabetic nephropathy
Correct Answer: C
Rationale: The 2026 ADA Standards of Care formally elevate cardiovascular and kidney
risk reduction to a co-primary treatment goal alongside glucose lowering. SGLT2
inhibitors are now positioned as core cardiorenal protective therapies irrespective of
A1C level. They can be continued in patients not on dialysis with eGFR <20 mL/min/1.73
m², and their benefits extend well beyond glycemic control. Sulfonylureas carry
hypoglycemia risk and weight gain; DPP-4 inhibitors have neutral CV effects at best;
thiazolidinediones cause fluid retention and are contraindicated in heart failure.
VERIFIED ✅ A+ GRADED
Q2: A 45-year-old African American male has resistant hypertension despite adherence
to maximum-dose ACE inhibitor, thiazide diuretic, and calcium channel blocker. His
,potassium is 4.2 mEq/L. Per the 2025 ACC/AHA Hypertension Guideline, what is the
next best step in management?
A. Add spironolactone 25 mg daily, as mineralocorticoid receptor antagonists are
fourth-line in resistant hypertension
B. Screen for primary aldosteronism regardless of potassium status, as the guideline
now recommends this for all resistant hypertension patients [CORRECT]
C. Increase the thiazide to chlorthalidone 50 mg daily, as it is more potent than
hydrochlorothiazide
D. Refer for renal denervation immediately, as it is first-line for resistant hypertension in
the 2025 guideline
Correct Answer: B
Rationale: The 2025 ACC/AHA guideline recommends screening for primary
aldosteronism in patients with resistant hypertension regardless of whether
hypokalemia is present, a major change from previous recommendations that required
hypokalemia. This change aims to increase detection rates. While spironolactone is an
effective fourth-line agent, identifying the underlying cause first is critical. Renal
denervation is reserved for select cases after comprehensive evaluation. VERIFIED ✅
A+ GRADED
Q3: A 62-year-old female with hypertension and overweight (BMI 32) has a PREVENT
10-year CVD risk score of 8.5%. Her BP is consistently 138/86 mmHg. According to the
2025 ACC/AHA guideline, what is the recommended approach?
A. Lifestyle modification for 6 months with reassessment; pharmacotherapy only if BP
remains ≥140/90 mmHg
B. Initiate antihypertensive medication now, as her PREVENT score ≥7.5% meets the
threshold for pharmacotherapy in stage 1 hypertension [CORRECT]
C. Start a GLP-1 receptor agonist for weight loss only, as blood pressure management
can wait until weight is reduced
D. Recheck BP in 3 months; the PREVENT calculator is only used for statin eligibility, not
hypertension
Correct Answer: B
Rationale: The 2025 ACC/AHA guideline uses the PREVENT risk calculator to guide
treatment decisions in stage 1 hypertension (130-139/80-89 mmHg). Adults with a
PREVENT 10-year CVD risk ≥7.5% should begin antihypertensive medication. The
,universal BP goal is <130/80 mmHg. Waiting for lifestyle modification alone in this
higher-risk patient would delay necessary risk reduction. VERIFIED ✅ A+ GRADED
Q4: A 70-year-old with HFrEF (EF 35%) on optimal GDMT presents with persistent
dyspnea. The cardiologist asks about adding finerenone. Which statement aligns with
2026 ADA and cardiology guidance?
A. Finerenone is contraindicated in HFrEF because it is a steroidal MRA with
progesterone-like effects
B. Finerenone is a non-steroidal MRA recognized in 2026 ADA for favorable heart failure
outcomes in patients with diabetes and should be considered for added cardiorenal
protection [CORRECT]
C. Finerenone should only be used if the patient has primary aldosteronism confirmed
by saline suppression testing
D. Finerenone is primarily indicated for hyperkalemia management in patients on ACE
inhibitors
Correct Answer: B
Rationale: The 2026 ADA Standards of Care recognize finerenone, a non-steroidal
mineralocorticoid receptor antagonist, for its favorable heart failure outcomes in
patients with diabetes. It provides cardiorenal protection distinct from steroidal MRAs
like spironolactone. It is not restricted to primary aldosteronism and does not treat
hyperkalemia—it requires potassium monitoring. VERIFIED ✅ A+ GRADED
Q5: A 55-year-old with type 2 diabetes and established ASCVD has LDL-C 110 mg/dL on
high-intensity statin. Per 2026 ADA lipid recommendations, what is the target LDL-C?
A. <100 mg/dL, as diabetes alone qualifies for moderate-intensity statin goals
B. <70 mg/dL with consideration of ezetimibe or PCSK9 inhibitor to achieve ≥50%
reduction [CORRECT]
C. <55 mg/dL is only for patients with familial hypercholesterolemia, not standard
ASCVD
D. <130 mg/dL is acceptable for patients over 50 years of age with diabetes
Correct Answer: B
Rationale: The 2026 ADA Standards recommend that patients with established ASCVD
require high-intensity statins, often with ezetimibe or PCSK9 inhibitors, to achieve LDL-C
<55 mg/dL and ≥50% reduction. However, <70 mg/dL represents the minimum
acceptable target for very high-risk patients; the aggressive <55 mg/dL goal applies to
, those with multiple major ASCVD events or one event plus multiple risk factors. The key
is intensified therapy beyond statin monotherapy. VERIFIED ✅ A+ GRADED
Q6: A 48-year-old female presents with episodic palpitations, chest tightness, and
dyspnea. ECG shows irregularly irregular rhythm with no discernible P waves. HR 142
bpm. BP 102/68 mmHg. What is the priority intervention?
A. Immediate synchronized cardioversion at 200 J, as she is hemodynamically unstable
B. Administer IV adenosine 6 mg rapid push to terminate the arrhythmia
C. Start IV heparin infusion and rate control with IV diltiazem; assess for hemodynamic
stability before cardioversion [CORRECT]
D. Give IV metoprolol 5 mg every 5 minutes up to 15 mg for immediate rate control
Correct Answer: C
Rationale: This patient has new-onset atrial fibrillation with rapid ventricular response.
While her BP is borderline, she is not in overt shock (systolic >100 mmHg). The priority
is anticoagulation (if not contraindicated) and rate control while determining if
cardioversion is needed. Adenosine is ineffective for AFib. Immediate cardioversion is
reserved for unstable patients (systolic <90 mmHg, acute MI, severe heart failure).
Diltiazem provides rapid rate control without the negative inotropy of beta-blockers in
acute settings. VERIFIED ✅ A+ GRADED
Q7: A 68-year-old male with anterior STEMI received primary PCI 3 days ago. He
develops sudden onset dyspnea, tachypnea, and jugular venous distension. Lung exam
reveals bilateral crackles. BP 84/52 mmHg. What is the most likely diagnosis and
immediate management?
A. Cardiogenic shock due to papillary muscle rupture; immediate IABP and emergency
surgery
B. Acute right ventricular infarction; give 2 liters of crystalloid bolus immediately
C. Free wall rupture with tamponade; immediate pericardiocentesis
D. Cardiogenic shock from extensive anterior infarction; initiate norepinephrine and
dobutamine, emergent echocardiography [CORRECT]
Correct Answer: D
Rationale: Post-STEMI cardiogenic shock most commonly results from extensive
myocardial damage rather than mechanical complications (which typically occur 3-7
days later). The presentation with hypotension, JVD, and pulmonary edema indicates
Newest Actual Exam Q&A | Verified Detailed Answers |
Graded A+ | Pass Guaranteed - A+ Graded
SECTION 1: CARDIOVASCULAR SYSTEM - NEWEST CONCEPTS
(30 Questions)
Q1: A 58-year-old patient with type 2 diabetes, eGFR 45 mL/min/1.73 m², and UACR 350
mg/g presents for diabetes management. According to the 2026 ADA Standards of
Care, which medication class should be prioritized as a co-primary therapeutic goal
alongside glucose lowering?
A. Sulfonylureas, as they provide rapid glucose reduction and are safe in CKD stage 3b
B. DPP-4 inhibitors, because they have proven cardiovascular benefit in all patients with
diabetes
C. SGLT2 inhibitors, due to their established cardiorenal protective benefits regardless
of baseline A1C or eGFR down to 20 mL/min/1.73 m² [CORRECT]
D. Thiazolidinediones, as they reduce insulin resistance and improve lipid profiles in
diabetic nephropathy
Correct Answer: C
Rationale: The 2026 ADA Standards of Care formally elevate cardiovascular and kidney
risk reduction to a co-primary treatment goal alongside glucose lowering. SGLT2
inhibitors are now positioned as core cardiorenal protective therapies irrespective of
A1C level. They can be continued in patients not on dialysis with eGFR <20 mL/min/1.73
m², and their benefits extend well beyond glycemic control. Sulfonylureas carry
hypoglycemia risk and weight gain; DPP-4 inhibitors have neutral CV effects at best;
thiazolidinediones cause fluid retention and are contraindicated in heart failure.
VERIFIED ✅ A+ GRADED
Q2: A 45-year-old African American male has resistant hypertension despite adherence
to maximum-dose ACE inhibitor, thiazide diuretic, and calcium channel blocker. His
,potassium is 4.2 mEq/L. Per the 2025 ACC/AHA Hypertension Guideline, what is the
next best step in management?
A. Add spironolactone 25 mg daily, as mineralocorticoid receptor antagonists are
fourth-line in resistant hypertension
B. Screen for primary aldosteronism regardless of potassium status, as the guideline
now recommends this for all resistant hypertension patients [CORRECT]
C. Increase the thiazide to chlorthalidone 50 mg daily, as it is more potent than
hydrochlorothiazide
D. Refer for renal denervation immediately, as it is first-line for resistant hypertension in
the 2025 guideline
Correct Answer: B
Rationale: The 2025 ACC/AHA guideline recommends screening for primary
aldosteronism in patients with resistant hypertension regardless of whether
hypokalemia is present, a major change from previous recommendations that required
hypokalemia. This change aims to increase detection rates. While spironolactone is an
effective fourth-line agent, identifying the underlying cause first is critical. Renal
denervation is reserved for select cases after comprehensive evaluation. VERIFIED ✅
A+ GRADED
Q3: A 62-year-old female with hypertension and overweight (BMI 32) has a PREVENT
10-year CVD risk score of 8.5%. Her BP is consistently 138/86 mmHg. According to the
2025 ACC/AHA guideline, what is the recommended approach?
A. Lifestyle modification for 6 months with reassessment; pharmacotherapy only if BP
remains ≥140/90 mmHg
B. Initiate antihypertensive medication now, as her PREVENT score ≥7.5% meets the
threshold for pharmacotherapy in stage 1 hypertension [CORRECT]
C. Start a GLP-1 receptor agonist for weight loss only, as blood pressure management
can wait until weight is reduced
D. Recheck BP in 3 months; the PREVENT calculator is only used for statin eligibility, not
hypertension
Correct Answer: B
Rationale: The 2025 ACC/AHA guideline uses the PREVENT risk calculator to guide
treatment decisions in stage 1 hypertension (130-139/80-89 mmHg). Adults with a
PREVENT 10-year CVD risk ≥7.5% should begin antihypertensive medication. The
,universal BP goal is <130/80 mmHg. Waiting for lifestyle modification alone in this
higher-risk patient would delay necessary risk reduction. VERIFIED ✅ A+ GRADED
Q4: A 70-year-old with HFrEF (EF 35%) on optimal GDMT presents with persistent
dyspnea. The cardiologist asks about adding finerenone. Which statement aligns with
2026 ADA and cardiology guidance?
A. Finerenone is contraindicated in HFrEF because it is a steroidal MRA with
progesterone-like effects
B. Finerenone is a non-steroidal MRA recognized in 2026 ADA for favorable heart failure
outcomes in patients with diabetes and should be considered for added cardiorenal
protection [CORRECT]
C. Finerenone should only be used if the patient has primary aldosteronism confirmed
by saline suppression testing
D. Finerenone is primarily indicated for hyperkalemia management in patients on ACE
inhibitors
Correct Answer: B
Rationale: The 2026 ADA Standards of Care recognize finerenone, a non-steroidal
mineralocorticoid receptor antagonist, for its favorable heart failure outcomes in
patients with diabetes. It provides cardiorenal protection distinct from steroidal MRAs
like spironolactone. It is not restricted to primary aldosteronism and does not treat
hyperkalemia—it requires potassium monitoring. VERIFIED ✅ A+ GRADED
Q5: A 55-year-old with type 2 diabetes and established ASCVD has LDL-C 110 mg/dL on
high-intensity statin. Per 2026 ADA lipid recommendations, what is the target LDL-C?
A. <100 mg/dL, as diabetes alone qualifies for moderate-intensity statin goals
B. <70 mg/dL with consideration of ezetimibe or PCSK9 inhibitor to achieve ≥50%
reduction [CORRECT]
C. <55 mg/dL is only for patients with familial hypercholesterolemia, not standard
ASCVD
D. <130 mg/dL is acceptable for patients over 50 years of age with diabetes
Correct Answer: B
Rationale: The 2026 ADA Standards recommend that patients with established ASCVD
require high-intensity statins, often with ezetimibe or PCSK9 inhibitors, to achieve LDL-C
<55 mg/dL and ≥50% reduction. However, <70 mg/dL represents the minimum
acceptable target for very high-risk patients; the aggressive <55 mg/dL goal applies to
, those with multiple major ASCVD events or one event plus multiple risk factors. The key
is intensified therapy beyond statin monotherapy. VERIFIED ✅ A+ GRADED
Q6: A 48-year-old female presents with episodic palpitations, chest tightness, and
dyspnea. ECG shows irregularly irregular rhythm with no discernible P waves. HR 142
bpm. BP 102/68 mmHg. What is the priority intervention?
A. Immediate synchronized cardioversion at 200 J, as she is hemodynamically unstable
B. Administer IV adenosine 6 mg rapid push to terminate the arrhythmia
C. Start IV heparin infusion and rate control with IV diltiazem; assess for hemodynamic
stability before cardioversion [CORRECT]
D. Give IV metoprolol 5 mg every 5 minutes up to 15 mg for immediate rate control
Correct Answer: C
Rationale: This patient has new-onset atrial fibrillation with rapid ventricular response.
While her BP is borderline, she is not in overt shock (systolic >100 mmHg). The priority
is anticoagulation (if not contraindicated) and rate control while determining if
cardioversion is needed. Adenosine is ineffective for AFib. Immediate cardioversion is
reserved for unstable patients (systolic <90 mmHg, acute MI, severe heart failure).
Diltiazem provides rapid rate control without the negative inotropy of beta-blockers in
acute settings. VERIFIED ✅ A+ GRADED
Q7: A 68-year-old male with anterior STEMI received primary PCI 3 days ago. He
develops sudden onset dyspnea, tachypnea, and jugular venous distension. Lung exam
reveals bilateral crackles. BP 84/52 mmHg. What is the most likely diagnosis and
immediate management?
A. Cardiogenic shock due to papillary muscle rupture; immediate IABP and emergency
surgery
B. Acute right ventricular infarction; give 2 liters of crystalloid bolus immediately
C. Free wall rupture with tamponade; immediate pericardiocentesis
D. Cardiogenic shock from extensive anterior infarction; initiate norepinephrine and
dobutamine, emergent echocardiography [CORRECT]
Correct Answer: D
Rationale: Post-STEMI cardiogenic shock most commonly results from extensive
myocardial damage rather than mechanical complications (which typically occur 3-7
days later). The presentation with hypotension, JVD, and pulmonary edema indicates
